Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AH1001
- Development stage
- Unknown
- Lead developer
- Beijing Kangchen Biological Technology
- Modality
- Small Molecules
01
Overview
AH1001 is a small-molecule hemostatic agent developed by Beijing Kangchen Biological Technology (also known as Konruns). It is classified as a registration category 3 chemical drug in China, specifically indicated for the management of uncontrolled bleeding during major surgical procedures. The drug is currently in an advanced stage of clinical development, with its status indicated as Phase 3 or under New Drug Application (NDA) review. While its specific molecular target and mechanism of action have not been publicly disclosed, AH1001 is positioned as a key candidate in Konruns' pipeline for surgical care, complementing its existing portfolio of biologic hemostatic products.
Beyond the preview
Go deeper on AH1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AH1001.